Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis

Ebina, K.; Etani, Y.; Tsuboi, H.; Nagayama, Y.; Kashii, M.; Miyama, A.; Kunugiza, Y.; Hirao, M.; Okamura, G.; Noguchi, T.; Takami, K.; Goshima, A.; Miura, T.; Fukuda, Y.; Kurihara, T.; Okada, S.; Nakata, K.

doi:https://doi.org/10.1007/s00198-022-06386-y

Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis

Ebina, K.; Etani, Y.; Tsuboi, H. et al.

Osteoporosis International, 2022, 33(8), 1807-1813

Number of Access:1,563（2025-07-24 02:12 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/93246

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
OsteoporosisInt_33_8_1807	pdf	None	1.87 MB	160	2023.12.07

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis
Creator	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 CreatorName Ebina, K.
	NRID 1000060898930 1000060898930 ORCID 0000-0001-5741-5969 0000-0001-5741-5969 researchmap permalink Yetani0302 Yetani0302 CreatorName Etani, Y.
	CreatorName Tsuboi, H.
	CreatorName Nagayama, Y.
	CreatorName Kashii, M.
	CreatorName Miyama, A.
	CreatorName Kunugiza, Y.
	NRID 1000010527708 1000010527708 CreatorName Hirao, M.
	CreatorName Okamura, G.
	CreatorName Noguchi, T.
	CreatorName Takami, K.
	CreatorName Goshima, A.
	CreatorName Miura, T.
	CreatorName Fukuda, Y.
	CreatorName Kurihara, T.
	NRID 1000030448435 1000030448435 ORCID 0000-0002-5107-8209 0000-0002-5107-8209 researchmap permalink okadaseiji okadaseiji Scopus Author ID 35079139100 35079139100 CreatorName Okada, S.
	NRID 1000000283747 1000000283747 researchmap permalink ken-nakata ken-nakata Scopus Author ID 7402151308 7402151308 CreatorName Nakata, K.
Subject	Bone mineral density
	Bone turnover marker
	Denosumab
	Postmenopausal osteoporosis
	Prior treatment
	Romosozumab
Description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00198-022-06386-y
Description	Ebina K., Etani Y., Tsuboi H., et al. Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis. Osteoporosis International 33, 1807 (2022)
Abstract	Summary: In patients with postmenopausal osteoporosis, prior osteoporosis treatment affected the bone mineral density increase of following treatment with 12 months of romosozumab, although it did not affect that of following treatment with 12 months of denosumab after romosozumab. Purpose: To investigate the effects of prior osteoporosis treatment on the response to treatment with romosozumab (ROMO) followed by denosumab (DMAb) in patients with postmenopausal osteoporosis. Methods: In this prospective, observational, multicenter study, treatment-naïve patients (Naïve; n = 55) or patients previously treated with bisphosphonates (BP; n = 37), DMAb (DMAb; n = 45) or teriparatide (TPTD; n = 17) (mean age, 74.6 years; T-scores of the lumbar spine [LS] − 3.2 and total hip [TH] − 2.6) were switched to ROMO for 12 months, followed by DMAb for 12 months. Bone mineral density (BMD) and serum bone turnover markers were evaluated for 24 months. Results: A BMD increase was observed at 12 and 24 months in the following patients: Naïve (18.2% and 22.0%), BP (10.2% and 12.1%), DMAb (6.6% and 9.7%), and TPTD (10.8% and 15.0%) (P < 0.001 between the groups at both 12 and 24 months) in LS and Naïve (5.5% and 8.3%), BP (2.9% and 4.1%), DMAb (0.6% and 2.2%), and TPTD (4.3% and 5.4%) (P < 0.01 between the groups at 12 months and P < 0.001 at 24 months) in TH, respectively. The BMD increase in LS from 12 to 24 months was negatively associated with the levels of bone resorption marker at 24 months. Incidences of major fragility fractures for the respective groups were as follows: Naïve (5.5%), BP (16.2%), DMAb (11.1%), and TPTD (5.9%). Conclusions: Previous treatment affected the BMD increase of following treatment with ROMO, although it did not affect that of following treatment with DMAb after ROMO.
Publisher	Springer Science and Business Media Deutschland GmbH
Source Title	Osteoporosis International
Volume (Issue)	33(8)
Page	1807-1813
Date of Issued	2022-08-01
Language	English
Handle URL	https://hdl.handle.net/11094/93246
PISSN	0937941X
eISSN	14332965
Relation.isVersionOf	DOI (Publisher Version) https://doi.org/10.1007/s00198-022-06386-y
Access Rights	open access
CopyRight	© 2022, International Osteoporosis Foundation and National Osteoporosis Foundation.
oaire:version	Accepted Manuscript
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Osteoporosis International. 2022, 33(8), p. 1807-1813
DC.title	Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis
DC.creator	Ebina, K.
	Etani, Y.
	Tsuboi, H.
	Nagayama, Y.
	Kashii, M.
	Miyama, A.
	Kunugiza, Y.
	Hirao, M.
	Okamura, G.
	Noguchi, T.
	Takami, K.
	Goshima, A.
	Miura, T.
	Fukuda, Y.
	Kurihara, T.
	Okada, S.
	Nakata, K.
DC.publisher	Springer Science and Business Media Deutschland GmbH
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2022-08-01
DC.identifier	https://doi.org/10.1007/s00198-022-06386-y
DC.subject	Bone mineral density
	Bone turnover marker
	Denosumab
	Postmenopausal osteoporosis
	Prior treatment
	Romosozumab
DC.description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00198-022-06386-y
DC.description	Ebina K., Etani Y., Tsuboi H., et al. Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis. Osteoporosis International 33, 1807 (2022)
DCTERMS.abstract	Summary: In patients with postmenopausal osteoporosis, prior osteoporosis treatment affected the bone mineral density increase of following treatment with 12 months of romosozumab, although it did not affect that of following treatment with 12 months of denosumab after romosozumab. Purpose: To investigate the effects of prior osteoporosis treatment on the response to treatment with romosozumab (ROMO) followed by denosumab (DMAb) in patients with postmenopausal osteoporosis. Methods: In this prospective, observational, multicenter study, treatment-naïve patients (Naïve; n = 55) or patients previously treated with bisphosphonates (BP; n = 37), DMAb (DMAb; n = 45) or teriparatide (TPTD; n = 17) (mean age, 74.6 years; T-scores of the lumbar spine [LS] − 3.2 and total hip [TH] − 2.6) were switched to ROMO for 12 months, followed by DMAb for 12 months. Bone mineral density (BMD) and serum bone turnover markers were evaluated for 24 months. Results: A BMD increase was observed at 12 and 24 months in the following patients: Naïve (18.2% and 22.0%), BP (10.2% and 12.1%), DMAb (6.6% and 9.7%), and TPTD (10.8% and 15.0%) (P < 0.001 between the groups at both 12 and 24 months) in LS and Naïve (5.5% and 8.3%), BP (2.9% and 4.1%), DMAb (0.6% and 2.2%), and TPTD (4.3% and 5.4%) (P < 0.01 between the groups at 12 months and P < 0.001 at 24 months) in TH, respectively. The BMD increase in LS from 12 to 24 months was negatively associated with the levels of bone resorption marker at 24 months. Incidences of major fragility fractures for the respective groups were as follows: Naïve (5.5%), BP (16.2%), DMAb (11.1%), and TPTD (5.9%). Conclusions: Previous treatment affected the BMD increase of following treatment with ROMO, although it did not affect that of following treatment with DMAb after ROMO.
DC.rights	© 2022, International Osteoporosis Foundation and National Osteoporosis Foundation.
DC.format	93246
citation_title	Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis
citation_author	Ebina, K.
	Etani, Y.
	Tsuboi, H.
	Nagayama, Y.
	Kashii, M.
	Miyama, A.
	Kunugiza, Y.
	Hirao, M.
	Okamura, G.
	Noguchi, T.
	Takami, K.
	Goshima, A.
	Miura, T.
	Fukuda, Y.
	Kurihara, T.
	Okada, S.
	Nakata, K.
citation_publisher	Springer Science and Business Media Deutschland GmbH
citation_language	English
citation_date	2022-08-01
citation_journal_title	Osteoporosis International
citation_volume	33
citation_issue	8
citation_firstpage	1807
citation_lastpage	1813
citation_doi	https://doi.org/10.1007/s00198-022-06386-y
citation_public_url	https://hdl.handle.net/11094/93246

Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis

Link to primary information

Item Information

Show details